For a 57-year-old woman with chronic neck and bilateral leg pain, osteopenia, normal renal function (eGFR 107 mL/min), and inadequate relief from cyclobenzaprine and methocarbamol, what short‑course NSAID regimen and adjunctive pharmacologic therapies should be recommended?

Recommended NSAID Regimen for Chronic Neck and Leg Pain

Given her normal renal function (eGFR 107), age 57, and failed conservative therapy, I recommend a short-course trial of scheduled oral NSAIDs—specifically meloxicam 7.5 mg daily for 7–10 days maximum—combined with a proton-pump inhibitor for gastroprotection, while simultaneously initiating gabapentin 300 mg at bedtime as adjunctive therapy for the neuropathic component suggested by her bilateral leg pain. 1

Rationale for NSAID Selection and Duration

The 2007 ACP/APS guidelines establish NSAIDs as more effective than acetaminophen for low back pain (approximately 10 points better on a 100-point pain scale), but emphasize using the lowest effective dose for the shortest period necessary due to well-documented gastrointestinal, cardiovascular, and renal risks 1. While her renal function is currently excellent, age >60 years places her at higher risk for NSAID-related complications 2.

Specific NSAID Recommendations:

• First choice: Meloxicam 7.5 mg daily for 7–10 days

  • Lower GI toxicity profile than non-selective NSAIDs
  • Once-daily dosing improves compliance
  • Recent evidence suggests short "pulse" courses (7 days) may provide extended analgesia beyond the treatment period while minimizing cumulative exposure 3

• Alternative: Ibuprofen 400 mg three times daily (maximum 3200 mg/day) for 7–10 days 2

  • If meloxicam unavailable or patient has prior positive response to ibuprofen
  • More frequent dosing may reduce compliance

• Ketorolac injection today is appropriate as planned, but limit to maximum 5 days total if considering oral continuation 2

Critical Safety Measures

Mandatory Gastroprotection:

Co-prescribe a proton-pump inhibitor (omeprazole 20 mg daily) during NSAID course 2. At age 57, she has moderate GI risk, and prophylaxis significantly reduces ulcer complications.

Cardiovascular Assessment:

Before prescribing, assess for:

• History of cardiovascular disease, hypertension, or heart failure
• Current anticoagulant use
• If cardiovascular risk factors present, consider limiting to 5 days or using acetaminophen + tramadol instead 4

Monitoring Requirements:

Given her age and planned NSAID use, baseline assessment should include:

• Blood pressure
• Renal function (already documented as normal)
• If NSAIDs extended beyond 2 weeks: repeat BUN/creatinine, monitor blood pressure 2

Adjunctive Pharmacologic Therapy

Neuropathic Pain Component:

Her bilateral leg pain with cervical and lumbar degenerative changes suggests possible radiculopathy. The evidence strongly supports adding:

Gabapentin: Start 300 mg at bedtime, titrate to 300 mg three times daily over 1 week, then increase weekly by 300 mg/day as tolerated to target 900–1800 mg/day in divided doses 5, 6

• First-line therapy for neuropathic pain per NeuPSIG guidelines 5
• Takes 6–8 weeks for full effect, aligning with her physical therapy timeline
• Start low due to sedation risk; bedtime dosing minimizes daytime impairment
• Alternative: Pregabalin 75 mg twice daily, titrate to 150 mg twice daily (faster titration but more expensive)

Antidepressant Option:

If gabapentin poorly tolerated or inadequate response after 4 weeks:

Duloxetine 30 mg daily for 1 week, then 60 mg daily 5, 6

• Effective for chronic musculoskeletal pain and neuropathic pain
• Addresses potential mood component common in chronic pain
• Nausea is main side effect; starting at 30 mg reduces this
• No significant cardiovascular or renal concerns

Muscle Relaxant Reconsideration

She previously tried cyclobenzaprine 10 mg without adequate relief. The FDA label indicates cyclobenzaprine exhibits dose-dependent efficacy, and she may not have received optimal dosing 7. However:

• Do NOT restart cyclobenzaprine at this time 8
• Muscle relaxants show efficacy only for acute low back pain (<4 weeks), not chronic pain 1, 8
• Her 1-month duration suggests transition to subacute/chronic phase
• Sedation risk compounds with gabapentin
• Methocarbamol already failed due to side effects

What NOT to Do

Avoid These Common Pitfalls:

1. Do not prescribe NSAIDs for >2 weeks without reassessment 1, 9

   • Adverse events increase with duration while analgesic benefit plateaus
   • If pain persists beyond 2 weeks of NSAIDs, escalate to gabapentin/duloxetine, not longer NSAID course

2. Do not combine multiple NSAIDs (including ketorolac injection + oral NSAID on same day without gap) 2

   • Additive toxicity without improved analgesia

3. Do not use systemic corticosteroids 10

   • No evidence of efficacy for nonspecific low back/neck pain
   • Significant adverse effects, especially with osteopenia

4. Avoid opioids at this stage 1, 6

   • Reserve for severe, disabling pain uncontrolled by above measures
   • She has not yet tried first-line neuropathic agents
   • Opioid evidence limited to modest short-term effects with substantial long-term risks

Osteopenia Management

Ensure she starts Caltrate 600+D3 immediately—call pharmacy to confirm pickup or arrange delivery. Untreated osteopenia increases fracture risk, which would significantly worsen her pain and function. This is non-negotiable for long-term morbidity reduction.

Treatment Algorithm Summary

Week 1:

• Ketorolac injection today
• Start meloxicam 7.5 mg + omeprazole 20 mg daily (7-day course)
• Start gabapentin 300 mg at bedtime
• Confirm Caltrate pickup
• Continue physical therapy

Week 2:

• Discontinue meloxicam after 7–10 days
• Increase gabapentin to 300 mg three times daily
• Reassess pain level

Weeks 3–8:

• Titrate gabapentin to 900–1800 mg/day based on response and tolerability
• Physical therapy continues
• If inadequate response at week 4: add duloxetine 30 mg daily × 1 week, then 60 mg daily

Reassessment at 8 weeks:

• If still inadequate relief: NOW refer to pain management (she declined initially but may reconsider after structured trial)
• Consider tramadol 50 mg 2–3 times daily as bridge if severe pain persists

This approach prioritizes safety while providing multimodal analgesia targeting both inflammatory and neuropathic mechanisms, aligns with her 8-week physical therapy timeline, and avoids the "NSAID trap" of prolonged use with diminishing returns and escalating risks.